
Opinion|Videos|January 6, 2025
An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Introduce the phase 2 study of loncastuximab plus rituximab in R/R FL presented at ASH 2024.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
4
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
5



















